Sugi Predict

Sugi Predict / Compounds / SCHEMBL4630905

SCHEMBL4630905

SCHEMBL4630905

COC(=O)c1cccc(C(F)(F)F)c1CBr

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.43
▸ LMNA P02545 3/20 0.41
▸ CTSS P25774 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CFTR P13569 5/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ PDK2 Q15119 2/20 0.41
▸ RBP4 P02753 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TAS2R14 Q9NYV8 2/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PDK1 Q15118 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ KCNK3 O14649 1/20 0.39
▸ KCNK9 Q9NPC2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28052334 0.88 NOTUM (0.41) NOTUMLMNACTSSGAACFTR
SCHEMBL27273620 0.86 CTSS (0.45) NOTUMLMNACTSSGAACFTR
SCHEMBL30935916 0.86 LMNA (0.42) NOTUMLMNACTSSGAACFTR
SCHEMBL30935926 0.85 CFTR (0.44) NOTUMLMNACTSSGAACFTR
SCHEMBL29041518 0.84 LMNA (0.52) LMNAGAACFTRTSHRALDH1A1
SCHEMBL30689795 0.80 TAS2R14 (0.52) NOTUMLMNAGAACFTRTSHR
SCHEMBL22403860 0.80 TAS2R14 (0.52) NOTUMLMNAGAACFTRTSHR
SCHEMBL5557509 0.80 LMNA (0.44) LMNACFTRTSHRALDH1A1KDM4E
SCHEMBL29151118 0.79 NOTUM (0.44) NOTUMCFTRPDK2KDM4EPDK1
SCHEMBL45490 0.79 LMNA (0.59) NOTUMLMNAGAACFTRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4602028-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2025-08-20 — — EP disclosed
US-20250230147-A1 LACTAMS AS CBL-B INHIBITORS GENENTECH, INC. (US) 2025-07-17 — — US disclosed
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250136590-A1 SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF NURIX THERAPEUTICS, INC. 2025-05-01 — — US disclosed
US-12234230-B2 Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof NURIX THERAPEUTICS, INC. (US) 2025-02-25 — — US disclosed
US-20240409555-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2024-12-12 — — US disclosed
WO-2024220626-A1 SMALL MOLECULE MODULATORS OF OGG1 AZKARRA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed
US-12049471-B2 Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof NURIX THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 — — WO disclosed
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 — — WO disclosed
WO-2012150202-A1 ISOINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-11-08 — — WO disclosed
EP-1924573-A1 B-RAF INHIBITORS AstraZeneca AB (SE) 2008-05-28 — — EP disclosed
EP-1519925-B1 OXAZOLE DERIVATIVES AND THEIR USE AS INSULIN SENSITIZERS HOFFMANN LA ROCHE (CH) 2007-09-12 — — EP disclosed
WO-2006079791-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2006-08-03 — — WO disclosed
EP-1519925-A1 OXAZOLE DERIVATIVES AND THEIR USE AS INSULIN SENSITIZERS F. HOFFMANN-LA ROCHE AG (CH) 2005-04-06 — — EP disclosed
US-6747049-B2 NON-INSULIN DEPENDENT DIABETES MELLITUS. HOFFMANN-LA ROCHE INC. 2004-06-08 — — US disclosed
WO-2004005266-A1 OXAZOLE DERIVATIVES AND THEIR USE AS INSULIN SENSITIZERS F. HOFFMANN-LA ROCHE AG (CH) 2004-01-15 — — WO disclosed
US-20040006116-A1 Oxazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-01-08 — — US disclosed
US-20030216571-A1 Antiallergens; antiinflammatory agents UBE INDUSTRIES, LTD. (JP) 2003-11-20 — — US disclosed
EP-1254897-A1 TRICYCLIC COMPOUNDS Ube Industries, Ltd. (JP) 2002-11-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049471-B2 Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof CBLB, CBL, CBLC NOTUM 2896/4885LMNA 1984/4885CTSS 802/4885
US-20240409555-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF CBLB, CBL, CBLC NOTUM 2896/4885LMNA 1984/4885CTSS 802/4885
US-20040006116-A1 Oxazole derivatives GPR119, IRS1, INSR NOTUM 349/4885LMNA 4592/4885CTSS 4848/4885
US-20250230147-A1 LACTAMS AS CBL-B INHIBITORS CBLB, CBL, CBLC NOTUM 2606/4885LMNA 2932/4885CTSS 1818/4885
US-12234230-B2 Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof CBL, CBLB, CBLC NOTUM 3183/4885LMNA 2268/4885CTSS 1175/4885
US-20250136590-A1 SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF CBL, CBLB, CBLC NOTUM 3183/4885LMNA 2268/4885CTSS 1175/4885
US-20030216571-A1 Antiallergens; antiinflammatory agents CYSLTR2, CYSLTR1, LTC4S NOTUM 456/4885LMNA 2810/4885CTSS 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.